Taysha Gene Therapies Investor Relations Material

Taysha Gene Therapies Inc. is a biotechnology company focused on developing gene therapies for the treatment of monogenic diseases of the central nervous system. The company leverages its adeno-associated virus (AAV) gene therapy platform to create treatments targeting rare genetic disorders, particularly those affecting the brain and spinal cord. Taysha's pipeline includes therapies aimed at conditions such as neurodegenerative and neurodevelopmental diseases, with a mission to provide life-changing treatments for patients with limited or no therapeutic options. The company is advancing its programs through research, clinical development, and regulatory processes. The company is headquartered in Dallas, Texas, and its shares are listed on the NASDAQ.